Key facts
- It has raised $4.8M; the latest was Seed Round ($2.9M) in Aug 2025.
- Notable investors include Brandon Capital, ANDHealth, Brandon Biocatalyst, Genesis Pre-Seed Fund, Tin Alley Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Mirugen
- ·The full record, as it builds
Funding rounds
No funding rounds for Mirugen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mirugen
Operator of a biotech start-up intended to develop gene therapy to stimulate retinal regeneration and treat blindness. The company is looking to switch on sight with a new treatment approach for conditions such as Retinitis Pigmentosa and Stargardt's disease, which harnesses the regenerative power of the retina's stem cells to prevent and reverse damage to the light-sensing photoreceptors in the back of the eye, enabling patients to get the treatment for incurable blindness.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2022
- Employees
- 3
- Website
- mirugen.com/
- Ownership
- Privately Held (backing)
Mirugen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mirugen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mirugen in its N-PORT filings yet. We sweep new filings monthly.